Cancer - CG Pharmaceuticals, Inc.

Cancer

Status:

Active, open to accrual

ClinicalTrials.gov:

NCT05249101

A Phase 1b/2, Dose-escalation, Randomized, Multicenter Study of Maintenance Ivaltinostat plus Capecitabine or Capecitabine Monotherapy in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on First Line FOLFIRINOX Chemotherapy

Drug

Ivaltinostat

Condition

Pancreatic cancer